The imminent pancreatic cancer trial PRIMUS001 (ISRCTN75002153) has the potential to personalize therapy for patients with pancreatic cancer. In this interview Derek Grose, MBChB, MRCP, FRCR, MD of the Beatson West of Scotland Cancer Centre, Glasgow, UK at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK provides an overview of the design and aims of the trial, in addition to the mutated pathway in the patients recruited.
Upcoming pancreatic cancer study: PRIMUS001
